The most frequent second event in FPD/AML patients is the somatic mutation of the unaffected allele of RUNX1 [10]; however, mutations in other genes such as CDC25C, CBL, FLT3, TP53, or ASXL1, among others, have also been described [31,32]. This evidence concerns the gene CBL and acute myeloid leukemia.